All PlansAdministrativeMedium impact
08.01.26e, Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi])
Independence Blue Cross·Medical Policy
We identified it
Jul 9, 2026
Summary
Failed to analyze policy change